Table 1. Baseline characteristic of patients and status after follow-up period.
| Time after follow-up | |||||
| Characteristics | Baseline (n = 662) | 1-year (n = 652) | 3-year (n = 515) | 5-year (n = 342) | 10-year (n = 89) |
| Age, (year, mean ± SD) | 36.4 ± 11.2 | 37.3 ± 11.2 | 39.4 ± 10.9 | 41.2 ± 10.9 | 48.3 ± 9.8 |
| Age (n, %) | |||||
| > = 50 | 90 (13.6) | 93 (14.2) | 88 (17.0) | 72 (17.6) | 33 (33.7) |
| Male, n (%) | 584 (88.2) | 574 (88.0) | 455 (77.8) | 297 (86.8) | 69 (69.7) |
| Route of transmission, n (%) | |||||
| Homosexual | 417 (63.0) | ||||
| Heterosexual | 103 (15.6) | NA | NA | NA | NA |
| Blood | 53 (8.0) | ||||
| Unclear/others | 89 (13.4) | ||||
| Opportunistic infection, n (%) | 212 (32.0) | NA | NA | NA | NA |
| HBsAg (+), n (%) | 43 (6.5) | NA | NA | NA | NA |
| HCV-Ab (+), n (%) | 24 (3.6) | NA | NA | NA | NA |
| Baseline ART regimen, n (%)† | NA | NA | NA | NA | |
| 2 NRTIs + NNRTI | 495 (74.8) | ||||
| 2 NRTIs + PI | 45 (6.8) | ||||
| 2 NRTIs + INRTI | 73 (11.0) | ||||
| Other | 49 (7.4) | ||||
| Plasma viral load (log10copies/mL) | 4.74 ± 0.77 | NA | NA | NA | NA |
| <5 | 407 (61.5) | ||||
| ≥5 | 240 (36.3) | ||||
| Mean time suppressed to VL <50 cps/ml (month) | 9.9 ± 17.2 | NA | 10.6 ± 18.0 | 12.9 ± 20.9 | 23.5 ± 32.2 |
| >6 month | 225 (34.0) | 216 (36.7) | 174 (42.6) | 67 (67.7) | |
| CD3+CD4+T counts (cells/μl) Ref (561–1137) | 226 (83,336) | 376 (244, 533) | 449 (303, 604) | 468 (352,623) | 500 (389, 653) |
| ~49 | 124 (18.7) | 4 (0.6) | 4 (0.8) | 2 (0.6) | 1 (1.1) |
| 50~99 | 56 (8.5) | 27 (4.1) | 4 (0.8) | 2 (0.6) | 0 (0.0) |
| 100–199 | 122 (18.4) | 83 (12.7) | 35 (6.8) | 10 (2.9) | 1 (1.1) |
| 200–349 | 215 (32.5) | 183 (28.1) | 125 (24.3) | 68 (19.9) | 14 (15.7) |
| 350–499 | 96 (14.5) | 168 (25.8) | 138 (26.8) | 109 (31.9) | 28 (31.5) |
| ≥500 | 49 (7.4) | 187 (28.7) | 209 (40.5) | 151 (44.2) | 45 (50.6) |
| CD3+CD8+T counts(cells/μl) Ref (404–754) | 789 (532,1045) | 732 (548, 969) | 699 (527, 925) | 666 (518,863) | 647 (515, 843) |
| ~499 | 147 (22.2) | 122 (18.7) | 111 (21.6) | 82 (24.0) | 20 (22.7) |
| 500–999 | 300 (45.3) | 380 (58.4) | 297 (57.8) | 208 (60.8) | 55 (62.5) |
| 1000–1499 | 151 (22.8) | 115 (17.7) | 93 (18.1) | 41 (12.0) | 8 (9.1) |
| ≥1500 | 64 (9.7) | 34 (5.2) | 13 (2.5) | 11 (3.2) | 5 (5.7) |
| CD4+CD45RA-/CD4+T (%) Ref (45.6–68.4) | 71.6 (61.5, 84.2) | 69.9 (60.0, 80.4) | 68.6 (59.3, 79.0) | 70.9 (61.5, 79.8) | 74.5 (66.4, 83.9) |
| CD4+CD45RA-T count (cells/μl) Ref (283–683) | 150 (73, 226) | 249 (175, 348) | 300 (217, 390) | 326 (246,417) | 374 (290, 456) |
| CD4+CD45RA+/CD4+T (%) Ref (31.6–54.4) | 28.6 (15.9, 38.5) | 30.1 (19.7, 40.0) | 31.3 (21.0, 40.7) | 29.2 (20.2,38.6) | 25.5 (16.1, 33.7) |
| CD4+CD45RA+/CD4+T Ref (206–530) | 62 (14,117) | 112 (50, 192) | 135 (69, 218) | 133 (79, 210) | 120 (66, 203) |
| CD4+CD28+/CD4+T (%) Ref (85.0–100.0) | 89.2 (75.0, 95.5) | 92.2 (82.8, 96.8) | 93.3 (86.5, 97.4) | 93.9 (86.9, 97.5) | 93.2 (86.9, 98.0) |
| CD8+CD28+/CD8+T (%) Ref (37.2–60.4) | 30.5 (21.7, 40.1) | 40.8 (31.5, 52.7) | 48.5 (38.6, 60.1) | 52.3 (42.0, 63.2) | 59.6 (44.0, 66.9) |
| CD8+HLA-DR+/CD8+T (%) Ref (6.3–23.8) | 63.2 (48.3, 74.2) | 40.3 (29.4, 52.9) | 37.3 (26.8, 48.9) | 35.2 (25.3, 45.6) | 34.9 (27.2, 49.4) |
| CD8+CD38+/CD8+T (%) Ref (32.4–57.4) | 79.8 (68.5, 89.3) | 51.6 (37.4, 65.4) | 44.7 (32.1, 57.3) | 41.6 (30.2, 54.1) | 31.0 (21.5, 44.8) |
| CD4+/CD8+T Ref (0.95–2.13) | 0.25 (0.12, 0.40) | 0.53 (0.28, 0.80) | 0.66 (0.41, 0.92) | 0.72 (0.47, 1.02) | 0.76 (0.57, 1.04) |
| > = 1.0 (n, %) | 8 (1.2) | 92 (14.1) | 102 (19.7) | 91 (26.5) | 28 (31.5) |
Abbreviations: †NRTIs: nucleoside reverse transcriptase inhibitor; NNRTI: Non-nucleoside reverse transcriptase inhibitor; INSTI: integrase strand transfer inhibitor; PI: protease inhibitor. Ref: Reference range based on healthy controls.